XTS Platform
Parkinson's Disease, ALS, and other neurodegenerative disorders
Preclinical/ResearchActive
Key Facts
Indication
Parkinson's Disease, ALS, and other neurodegenerative disorders
Phase
Preclinical/Research
Status
Active
Company
About X-tosis
X-tosis is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach targeting mitochondrial dysfunction via modulation of the VDAC1 protein, a mechanism implicated in over 18 neurological and systemic disorders. Its lead program, XTS001, has demonstrated compelling preclinical efficacy in Alzheimer's models, showing improvements in learning, memory, neuronal survival, and reduction of key pathologies. X-tosis is positioning itself as a platform company with a potentially disease-modifying treatment for a high-unmet-need market.
View full company profile